Zimmer Biomet Cuts Up to 580 Jobs in Winterthur as Restructuring Accelerates

Zimmer Biomet announced on September 9 that it will cut up to 580 jobs at its Winterthur, Switzerland manufacturing plant, reducing the 730-person workforce to roughly 140 employees. The cuts represent 3.4% of the company’s 17,000 global workforce and are part of a restructuring to simplify production networks and boost efficiency. The decision is not yet final, as the company has begun a consultation process with workers and their representatives.

Why Zimmer Biomet is restructuring Winterthur

Zimmer Biomet acquired the Winterthur site in 2003 through its USD 3 billion acquisition of Swiss orthopedic company Centerpulse. The company says the restructuring is necessary to strengthen long-term competitiveness and simplify its global manufacturing footprint. The proposal affects production operations specifically, though the company has not disclosed which departments will be hit hardest or where jobs will be relocated.

Local government and workers push back

Winterthur city president Stefan Fritschi called the cuts “a very bad message” that the city did not foresee. He criticized the company for focusing purely on shareholder returns despite strong quarterly results and financial health. Fritschi and city councillor Kaspar Bopp are meeting with Zimmer Biomet leadership to argue against the cuts and demand socially responsible implementation. Fritschi called moving specialized expertise abroad “dangerous and irresponsible.”

Stock falls but consultation process offers uncertainty

Zimmer Biomet shares closed at USD 92.44 on September 10, down 2.29% from USD 94.61 the prior day. The stock has retreated from August highs above USD 100 and is trading below its 50-day and 200-day moving averages. Technical indicators show the relative strength index near 30, suggesting oversold conditions. The company has not set a timetable for the consultation, meaning the final job count could change. Analyst consensus targets USD 104.42, implying 12% upside from current levels.

Meyka data and valuation context

Meyka grades Zimmer Biomet a B+ with a buy recommendation, citing strong fundamentals despite near-term headwinds. The stock trades at a 22.6 price-to-earnings ratio, below its 11.02 TTM multiple, and carries a 1.03% dividend yield. The 12-month price forecast of USD 84.43 sits 9.7% below current levels, reflecting uncertainty around the restructuring and broader medtech sector pressures. Earnings are scheduled for November 4, 2026.

Final Thoughts

Zimmer Biomet’s Winterthur cuts signal aggressive cost management but carry execution risk. With analyst targets at USD 104.42 and Meyka grading the stock B+, the market sees value if the restructuring succeeds. Investors should monitor the consultation outcome and Q3 earnings in November.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.